Clinical & Scientific

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.

A new program in Nevada is using breath-based tech to tackle first responder burnout. But can a simple device truly change the complex health of those who serve?

A pilot study shows light therapy improving memory in MCI patients, fueling the at-home neurotech boom. But can Vielight turn scientific promise into market reality?

A major survey names Bonafide Health's products #1 in their class. We explore the strategy behind the headlines and what it signals for women's health.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Brixton Metals unveils stunning high-grade silver at its historic Langis Project, pushing aggressively toward a maiden resource and commercial viability.

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

Crescom's AI is being tested at Mass General Brigham, aiming to ease radiologist burnout and establish a critical foothold in the competitive US MedTech market.

A new surgical method called SMART, developed at Delray Medical Center, uses biological scaffolds to overcome the failure of sutures in critical muscle injuries.

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

Newcore Gold's latest deep drilling at its Enchi project in Ghana extends high-grade gold zones, signaling major resource growth ahead of a pivotal study.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.